Longevity Market

9 February 2026.

Visiongain has published a new report entitled Longevity Market Report 2026-2036 (Including Impact of U.S. Trade Tariffs): Forecasts by Product & Services ((Product (Dietary Supplements, Therapeutic Drugs and Biologics, Anti-aging Skin Care Products, Telehealth Solutions, Medical Devices, Health Monitoring Devices), Service (Health and Wellness Services, Fitness Programs, Life Extension Therapies, Genetic Testing, Nutraceutical Services/Programs)), by Intervention ((Modern or Clinical Interventions (Immunotherapy, Gene Therapy, Senolytic Drug Therapy, Others), Traditional Alternative Medicine and Botanicals (Traditional Chinese Medicine, Ayurveda, Naturopathic Medicine, Others), Body Healing (Yoga, Acupuncture and Massage, Chiropractic, Qigong and Tai chi, Kinesiology, Reflexology, Eurythmy, Others), Mind Healing (Meditation & Mindfulness, Relaxation, Others), External Energy Healing(Magnetic and Electromagnetic Therapy, Reiki, Chakra Healing, Others), Sensory Healing (Aromatherapy, Sound Healing)), by Application (Non-Clinical Applications (Preventive Wellness, Anti-aging and Skin Health, Stress Management and Cognitive Enhancement, General Longevity and Vitality, Others), Clinical Applications (Cancer, Cardiovascular Diseases, Diabetes, Others), by Distribution Channel (Online Retail, Pharmacies, Health and Wellness Stores, Direct Sales, Hospitals/Clinical Settings), by End-users (Individuals, Healthcare Providers, Fitness Centres, Corporate Wellness Programs, Research Institutions) AND Regional and Leading National Market Analysis PLUS Analysis of Leading Companies.

The global longevity market is estimated at US$746.00 billion in 2026 and is projected to grow at a CAGR of 8.6% during the forecast period 2026-2036.

Longevity is increasingly moving beyond its origins as a consumer wellness trend to become a core component of healthcare strategy. Insurers, employers, pharmaceutical companies and healthcare providers are stepping up investment in prevention and early intervention, as ageing populations place sustained pressure on healthcare budgets, workforce productivity and long-term care capacity. The emphasis is shifting away from standalone solutions toward continuous risk assessment, clinical monitoring and integrated care models designed to delay or prevent the onset of chronic disease.

This transition is reshaping market dynamics. Longevity-related data, analytics and digital infrastructure are becoming central to population health management, clinical decision-making and upstream pharmaceutical development. At the same time, improving regulatory clarity and early reimbursement pilots are helping to reduce adoption risk and support scalable implementation. As institutional purchasers increasingly replace consumer-led demand, longevity is emerging as a strategic, long-term healthcare investment category with the potential to deliver both clinical and economic value.

Impact of US Trade Tariffs on the Global Longevity Market

U.S. trade tariffs are placing indirect cost pressure on the global longevity market by increasing the price of critical imported inputs, including biomanufacturing equipment, laboratory reagents and consumables, sensors, and precision electronics. Many of these components are sourced from China, Europe and East Asia, and higher input costs are affecting research budgets and production economics across the sector. While most longevity products are not directly tariffed, the impact is felt most acutely by startups and mid-sized companies developing advanced therapies, diagnostics and data-driven longevity platforms, where margins and funding flexibility are more limited.

In response, companies are accelerating supply-chain diversification strategies, including relocating selected manufacturing steps to the U.S. or allied markets and shifting sourcing to tariff-neutral regions such as Mexico and parts of Southeast Asia. This trend is particularly visible in bioprocessing equipment, diagnostic tools and wearable technologies linked to preventive health and monitoring. Although these adjustments improve long-term supply resilience, they also require higher upfront investment and longer development timelines, which may slow the pace of new product launches in the near term as trade conditions remain fluid.

Rising Consumer Demand for Proactive and Personalised Healthspan Interventions

Consumers are increasingly prioritising proactive and tailored healthspan interventions, driving sustained demand across the global longevity market. This shift reflects growing awareness of preventive health, early risk management and long-term wellbeing, particularly among mid-life and ageing populations. While both products and services continue to contribute to market expansion, the services segment currently accounts for a substantial share of market activity and is expected to grow at a faster pace, supported by its ability to deliver accessible, scalable and continuously engaging interventions.

Longevity-focused services integrate diagnostics, personalised guidance and ongoing monitoring, enabling sustained consumer participation and more measurable health and lifestyle outcomes over time. Product innovation continues to complement this trend. On 13^th March 2025, Elysium Health announced the launch of COFACTOR, a collagen-based formulation designed to support multiple pathways associated with collagen decline and positioned within broader healthy ageing routines. In parallel, pharmaceutical and health technology companies are expanding AI-enabled remote monitoring and digital health platforms, supporting predictive interventions and personalised engagement models that further reinforce long-term participation in longevity-focused care.

How will this Report Benefit you?

Visiongain’s 531-page report provides 223 tables and 372 charts/graphs. Our new study is suitable for anyone requiring commercial, in-depth analysis for the dietary supplements, therapeutic drugs and biologics, anti-aging skin care products manufacturing market, along with detailed segment analysis in the market. Our new study will help you evaluate the overall global and regional market for longevity. Get financial analysis of the overall market and different segments including product, service, intervention, application, distribution channel, end-user, and capture higher market share. We believe that there are strong opportunities in this fast-growing longevity market. See how to use the existing and upcoming opportunities in this market to gain revenue benefits in the near future. Moreover, the report will help you to improve your strategic decision-making, allowing you to frame growth strategies, reinforce the analysis of other market players, and maximise the productivity of the company.

What are the Current Market Drivers?

Advances in AI, Genomics and Regenerative Medicine Are Expanding the Longevity Market

Advances in artificial intelligence, genomics and regenerative medicine are strengthening both the development pipeline and the scalability of the longevity market. AI-driven drug discovery platforms are accelerating early-stage research by improving target identification and compound design for age-related diseases, while genomic and regenerative approaches are enabling more precise, mechanism-led therapeutic development. These technologies are shortening discovery timelines and supporting more efficient translation into clinical programmes, particularly in oncology, metabolic and organ-specific age-related conditions.

Companies such as Insilico Medicine are using AI platforms, including Pharma.AI, to advance candidates across fibrosis, oncology and other age-associated indications. In parallel, Life Biosciences is progressing regenerative medicine programmes based on partial epigenetic reprogramming for conditions such as optic neuropathies and liver disease. A notable milestone occurred on 11th December 2025, when Insilico Medicine announced a licensing agreement with Taigen Biotechnology to develop and commercialise an AI-designed prolyl hydroxylase (PHD) inhibitor for anaemia associated with chronic kidney disease.

As these innovation pathways expand, demand is increasing for specialised biologics reagents, gene-editing tools and multi-omics validation capabilities, creating opportunities for contract research organisations in hubs such as the U.S. and Singapore. At the same time, smaller precision-medicine firms are finding competitive advantage by offering agile biomarker screening and analytics services, supporting the efficient deployment of personalised, longevity-aligned therapies.

Growing Emphasis on Digital Health, Remote Monitoring and Longevity Clinics

Digital health platforms, remote monitoring technologies and longevity clinics are increasingly shaping how preventive care is delivered and scaled within the longevity market. Rather than episodic consultations, these models support continuous risk assessment, longitudinal monitoring and personalised care pathways, improving engagement and resilience across ageing populations. Their integration is strengthening market adoption while placing greater emphasis on data infrastructure, interoperability and regulatory compliance.

On 25th November 2024, Teladoc Health announced an expansion of its platform with advanced AI-enabled capabilities for hospitals and health systems, enhancing remote monitoring, virtual care delivery and clinical oversight. While not branded specifically as longevity modules, these capabilities strengthen the foundation for managing chronic, age-related conditions through scalable digital care. Separately, on 27th May 2025, Midi Health launched an insurance-covered longevity-focused care programme for women, reported by Axios as being reimbursed by private insurers across the United States. This development marks an important shift toward payer-supported telehealth delivery for longevity-aligned services.

As subscription-based longevity services expand, telehealth providers in the U.S. and Europe are well positioned to benefit from expertise in remote monitoring and predictive analytics, while smaller digital health firms can compete by focusing on specialised, condition-specific monitoring solutions that support sustained engagement and personalised preventive care.

Where are the Market Opportunities?

Expansion of AI-Enabled Drug and Biomarker Discovery

The longevity market presents a growing opportunity in AI-enabled drug discovery and biomarker development, as pharmaceutical companies, medtech firms and specialised longevity players increasingly adopt artificial intelligence and machine learning to improve research efficiency and clinical relevance. AI-driven approaches are being used to analyse complex clinical, physiological and digital health datasets, supporting faster identification of disease signals, risk markers and therapeutic targets associated with ageing and age-related conditions. This shift is helping reduce discovery timelines, improve prioritisation of development programmes and strengthen the translational pathway from research to clinical application.

Regulatory engagement is reinforcing this opportunity. In 2024, the U.S. Food and Drug Administration announced that it is testing AI and machine-learning approaches to predict and detect Parkinson’s disease symptoms, including freezing of gait, using data derived from wearables and smartphones, with the aim of establishing best practices for digital biomarkers. In parallel, in June 2024, the FDA granted premarket approval to Endotronix’s Cordella Pulmonary Artery Sensor System, a remote haemodynamic monitoring device designed to support home-based management of NYHA Class III heart failure patients.

Competitive Landscape

The major players operating in the longevity market are AbbVie Inc., Alkahest, Inc., Bristol-Myers Squibb Company, CELLINK, Elysium Health, GSK plc, Juvenescence Ltd., Insilico Medicine, Life Biosciences, Inc., Rejuvenate Bio, and Serina Therapeutics, Inc.These major players operating in this market have adopted various strategies comprising M&A, collaborations, investment in R&D, regional business expansion, partnerships, and new product launch.

Recent Developments

On 12^th December 2025, Insilico Medicine, a clinical-stage biotechnology firm using generative artificial intelligence for drug discovery, announced an exclusive licensing agreement with TaiGen Biotechnology to develop and commercialise ISM4808, an AI-designed prolyl hydroxylase domain (PHD) inhibitor for the treatment of anaemia associated with chronic kidney disease (CKD) across the Greater China region.
On 7^th April 2025, GSK plc entered a multi-program licensing agreement with South Korea’s ABL Bio to leverage ABL Bio’s Grabody-B blood-brain barrier shuttle platform in the development of novel therapeutics for neurodegenerative diseases.
On 13th March 2025, Elysium Health announced the launch of COFACTOR™, a new collagen-focused dietary supplement positioned around age-related collagen decline. The product combines collagen peptides with nicotinamide riboside (NR), hyaluronic acid and vitamin C in a four-component formulation designed to support collagen production and skin structure.

About Visiongain

Established in 1998, Visiongain is an independent publisher of analyst-led market intelligence, delivering data-driven research, forecasts, and strategic insight across global industries and emerging markets. Visiongain supports evidence-based decision-making for investment, procurement, and long-term strategic planning.